ESH CLL 2022 | How CLL cells suppress T-cell function
Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, discusses some important points from his presentation at ESH CLL 2022, which focused on how chronic lymphocytic leukemia (CLL) cells suppress T-cell function and the implications this has for CLL treatment. Dr Kater first explains the current use of novel agents such as Bruton’s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors in CLL treatment, and the future use of chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies. Dr Kater then discusses various ways in which CLL cells cause T-cell dysfunction and pseudo-exhaustion, which is currently being investigated and is important in improving CLL treatment in the future. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022.
Disclosures
Research funding Abbvie, Gennetech, Janssen, AZ, BMS
